3-(甲氧羰基)-1H-吡唑-5-羧酸 | 54866-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(甲氧羰基)-1H-吡唑-5-羧酸
• 英文名称: 3-(Methoxycarbonyl)-1H-pyrazole-5-carboxylic acid
• 英文别名: 5-methoxycarbonyl-1H-pyrazole-3-carboxylic acid
• CAS: 54866-86-3
• 化学式: C₆H₆N₂O₄
• mdl: MFCD09859216
• 分子量: 170.12
• InChiKey: VZUHHVCEVDUQHQ-UHFFFAOYSA-N

物化性质

• 熔点：
  158-160
• 沸点：
  461.5±30.0 °C(Predicted)
• 密度：
  1.527±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090

反应信息

• 作为产物：
  描述：

  azanide;(5-methoxycarbonyl-1H-pyrazole-3-carbonyl)oxy-trimethylazanium 生成 3-(甲氧羰基)-1H-吡唑-5-羧酸
  参考文献：
  名称：

  NEMATOLLAHI G.; KASINA S., J. CHEM. SOC., CHEM.COMMUN , 1974, NO 19, 775

  摘要：

  DOI：

文献信息

• Pyrazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1433788A1

  公开（公告）日：2004-06-30

  The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I的化合物，其中R0；R1；R2；R3；R4；Q；V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血凝酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在的情况，或者用于治疗或预防需要抑制因子Xa和/或因子VIIa的情况。此外，本发明涉及式I化合物的制备方法，它们的使用，特别是作为药物活性成分以及含有它们的药物制剂。
• Monocyclic L-nucleosides, analogs and uses thereof
  申请人：——

  公开号：US20030018186A1

  公开（公告）日：2003-01-23

  Novel monocyclic L-Nucleoside compounds have the general formula 1 Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

  新型单环L-核苷化合物的一般式为1。这些化合物的实施形式被认为对治疗各种疾病有用，包括感染、寄生虫感染、肿瘤和自身免疫性疾病。从机制上看，这些新型化合物的实施形式显示出免疫调节活性，并有望用于调节细胞因子模式，包括调节Th1和Th2反应。
• PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
  申请人：NAZARE Marc

  公开号：US20100010045A1

  公开（公告）日：2010-01-14

  The present invention is directed to a compound of formula I, in which R 0 ; R 1 ; R 2 ; R 3 ; R 4 ; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic effect and is suitable, for example, for the therapy and prophylaxis of a cardio-vascular disorder like a thromboembolic disease or restenosis. It is a reversible inhibitor of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore is directed to a process for the preparation of the compound of formula I, and pharmaceutical preparation comprising it.

  本发明涉及一种化合物I，其中R0; R1; R2; R3; R4; Q; V，G和M具有下面指示的含义。化合物I是一种药理活性化合物。它表现出强烈的抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞性疾病或再狭窄。它是血凝酶酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于存在因子Xa和/或因子VIIa不良活性的情况或预防因子Xa和/或因子VIIa抑制剂治疗或预防的情况。此外，本发明还涉及一种制备化合物I的方法和包含它的药物制剂。
• Compounds modulating c-fms and/or c-kit activity and uses therefor
  申请人：Zhang Jiazhong

  公开号：US20090076046A1

  公开（公告）日：2009-03-19

  Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

  提供了对受体蛋白酪氨酸激酶c-kit和/或c-fms活性的化合物。还提供了用于治疗c-kit介导的疾病或病状和/或c-fms介导的疾病或病状的组合物，以及使用它们的方法。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Zhang Jiazhong

  公开号：US20110112127A1

  公开（公告）日：2011-05-12

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on Fms protein kinase, or on Fms and Kit protein kinase, or on Fms and Flt-3 protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Fms protein kinase, Kit protein kinase, or Flt-3 protein kinase including rheumatoid arthritis, osteoarthritis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, acute myeloid leukemia, melanoma, multiple myeloma, metastatic breast cancer, prostate cancer, pancreatic cancer, neurofibromatosis, brain metastases, and gastrointestinal stromal tumors.

  本文描述了化合物及其盐、制剂、结合物、衍生物、形式和用途。在某些方面和实施方式中，所述化合物或其盐、制剂、结合物、衍生物或形式对Fms蛋白激酶、或对Fms和Kit蛋白激酶、或对Fms和Flt-3蛋白激酶具有活性。还描述了使用它们治疗与Fms蛋白激酶、Kit蛋白激酶或Flt-3蛋白激酶活性相关的疾病和病况的方法，包括类风湿性关节炎、骨关节炎、多发性硬化症、阿尔茨海默病、帕金森病、肾小球肾炎、间质性肾炎、红斑狼疮性肾炎、肾小管坏死、糖尿病肾病、肾肥大、急性髓系白血病、黑色素瘤、多发性骨髓瘤、转移性乳腺癌、前列腺癌、胰腺癌、神经纤维瘤病、脑转移和胃肠道间质肿瘤。